Health Headlines: COVID Inquiry, CBD Access, and Opioid Sentencing
A comprehensive summary of recent health news highlights The Lancet's refusal to assist a U.S. Senate COVID-19 inquiry, calls for legal updates on cannabidiol access, Purdue Pharma penalization delays, and advancements in Medicare device coverage. Additionally, news includes initiatives to streamline authorization requirements and developments in the U.S. marijuana industry.
The Lancet, a prominent medical journal, announced it would not comply with a U.S. Senate inquiry into the origins of the COVID-19 pandemic. Richard Horton, the editor-in-chief, revealed this decision during an event in Barcelona, emphasizing the journal's position on the matter.
In legislative developments, former U.S. President Donald Trump urged Congress to modernize laws ensuring access to cannabidiol (CBD) products, advocating for comprehensive availability of such substances to the public.
Meanwhile, Purdue Pharma faces a delay in sentencing for its role in the opioid crisis, as a federal judge allowed further public engagement in the legal proceedings. Such delays illustrate the complex and ongoing challenges surrounding healthcare and regulatory accountability.
(With inputs from agencies.)
ALSO READ
The Rise of Tailored Motor Insurance in India
SBI General Insurance Achieves Robust Financial Growth in FY26
U.S. Justice Department Eases Marijuana Restrictions, Paving Way for Industry Growth
U.S. Justice Department Reshapes Marijuana Policy, Easing Decades-Old Restrictions
Fast-Tracked Future: Medicare Speeds Up Device Coverage
Google News